Risempn 2026 Can We Engineer Disease Trajectories In Mpns?

Evento RES · di Xenia Sas Di Mazza Francesca & C. · Roma · 6 nov 2026

Crediti ECM
14
1 all'ora
Costo
Gratis
Durata
14 ore
Inizio
6 nov 2026
tra 29 giorni
Dove
Courtyard By Marriott Rome Central Park
Via Giuseppe Moscati, 7, Roma (RM)

In sintesi

A cura della redazione di Trova ECM

Questo corso ECM di tipo RES è offerto da Xenia Sas Di Mazza Francesca & C. e assegna 14 crediti ECM. L'obiettivo formativo è: 2 - Linee guida - protocolli - procedure.

Si affrontano le neoplasie mieloproliferative osservando come cambiano nel tempo e quali strumenti possono incidere sul loro decorso: dalle alterazioni biologiche e dal rischio vascolare fino alla scelta e all’associazione delle terapie, alla diagnosi molecolare e al trapianto. I contenuti sono utili soprattutto a chi segue persone con patologie ematologiche, nei servizi di ematologia e nei percorsi di oncologia e medicina trasfusionale, per orientare meglio monitoraggio, intensificazione terapeutica e decisioni condivise. La partecipazione è gratuita, in presenza, e dà diritto a 14 crediti ECM.

Scheda rapida

Provider
Xenia Sas Di Mazza Francesca & C.37 corsi in calendario
Tipologia
ResidenzialeCongresso, simposio, conferenza o seminario
Crediti ECM
1414 ore
Costo
Gratis
Per chi
  • Medico Chirurgo · 9 discipline
    • Farmacologia E Tossicologia Clinica
    • Oncologia
    • Genetica Medica
    • Patologia Clinica (Laboratorio Di Analisi Chimico-Cliniche E Microbiologia)
    • Biochimica Clinica
    • Medicina Trasfusionale
    • Medicina Generale (Medici Di Famiglia)
    • Ematologia
    • Anatomia Patologica
Dove
Courtyard By Marriott Rome Central ParkVia Giuseppe Moscati, 7, Roma (RM)
Quando
dal 6 nov 2026 al 7 nov 2026
Rilevanza
Internazionale
Verifica finale
test online
Faculty
24 docenti · 2 responsabili scientifici
Posti
70
Sponsor
Con il contributo non vincolante di GLAXO, NOVARTIS, AOP, SOBI, COGENT BIO, INCYTE, ITALFARMACO, KARTOS - TELIOS, TAKEDA, PHARMALINE, SUMITOMO
ID evento
493199edizione 1

Programma

DAY 1 — Friday, 6 November 2026

06/11/2026

  • 08:50–08:55 Welcome (Alessandro Lucchesi, Gerardo Musuraca) — Congress Presidents
  • 08:55–09:15 RISE LECTURE I (Tiziano Barbui) — Distinguished Chair
  • 09:20–10:35 Session 1— Blueprint: the biological levers we can actually pull — From clonal aging to early interception: CHIP clinics as a model for MPN prevention (Hans Hasselbalch)
  • 09:20–10:35 Session 1— Blueprint: the biological levers we can actually pull — Inflammasome activation and IL-1 in MPNs: inflammation as a targetable biological lever (Francisca Ferrer-Marín)
  • 09:20–10:35 Session 1— Blueprint: the biological levers we can actually pull — Metabolic vulnerabilities of the JAK2-mutant clone: immune evasion and therapeutic windows (Nageswara Rao Tata)
  • 09:20–10:35 Session 1— Blueprint: the biological levers we can actually pull — Metabolic reprogramming in the MPN niche: lactate, immune escape, and targetable vulnerabilities (Daniele Tibullo)
  • 09:20–10:35 Session 1— Blueprint: the biological levers we can actually pull — Discussion: “Which lever first: clone, niche, vessel, or host?”
  • 10:35–10:50 Coffee Break
  • 10:50–12:05 Session 2 — MF: build the platform, then add the modifier — Dynamic risk in myelofibrosis: anaemia as trajectory sensor and the first readable signal of disease modification (Alessandro Lucchesi)
  • 10:50–12:05 Session 2 — MF: build the platform, then add the modifier — First-line MF: phenotype-guided JAK platform selection and the anaemia trade-off (Francesca Palandri)
  • 10:50–12:05 Session 2 — MF: build the platform, then add the modifier — MF combination landscape: emerging combinations and where they fit the platform (John Mascarenhas)
  • 10:50–12:05 Session 2 — MF: build the platform, then add the modifier — MDM2/p53 and clone-stress strategies: from biology to combination rationale in MF (Florian Heidel)
  • 12:05–12:20 BRIDGE LECTURE I (Haifa Kathrin Al-Ali) — Standalone — connects the MF therapeutic platform (Session 2) to the strategic discussion.
  • 12:20–12:50 STRATEGIC DIALOGUE — Engineering the MF trajectory: a transatlantic perspective (Francesco Passamonti, Tania Jain) — Francesco Passamonti — European perspective: sequencing in the real world, registry signals, and the pragmatic framework (10 min); Tania Jain — US perspective: molecular risk architecture, transplant positioning, and the MDS/MPN boundary as a trajectory signal (10 min); Moderated exchange: 10 min
  • 12:50–14:05 Session 3 — The rational add-on toolbox: epigenetic, signalling , and erythroid targets — BET/HDAC/LSD1 inhibitors in MF: what epigenetic modifiers really change (Andrea Patriarca)
  • 12:50–14:05 Session 3 — The rational add-on toolbox: epigenetic, signalling , and erythroid targets — Non-JAK resistance nodes as combo targets: PI3Kδ, PIM, and CDK8-19 inhibitors in the synergy playbook (Michael Loschi)
  • 12:50–14:05 Session 3 — The rational add-on toolbox: epigenetic, signalling , and erythroid targets — Iron metabolism as a biological lever: hepcidin, erythroferrone, and the logic of pathway interference (Domenico Girelli)
  • 12:50–14:05 Session 3 — The rational add-on toolbox: epigenetic, signalling , and erythroid targets — Activin ligand traps and TGF-β pathway modulators for MF anaemia: clinical evidence and positioning (Giuseppe Palumbo)
  • 12:50–14:05 Session 3 — The rational add-on toolbox: epigenetic, signalling , and erythroid targets — Discussion: “Mechanism → positioning: how to avoid ‘combo tourism’.”
  • 14:05–15:00 Lunch + Industry Lunch Symposium (Slot 1) — Sponsor tbd.
  • 15:00–16:15 Session 4 — PV and ET: upstream trajectory change (before it becomes irreversible) — ET beyond cytoreduction: where epigenetic modifier strategies belong (Erika Morsia)
  • 15:00–16:15 Session 4 — PV and ET: upstream trajectory change (before it becomes irreversible) — Deceptive calm: acquired coagulopathy in ET, from occult bleeding risk to unpredictable thrombotic phenotypes (Elena Rossi)
  • 15:00–16:15 Session 4 — PV and ET: upstream trajectory change (before it becomes irreversible) — Masked polycythaemia vera and long-term interferon response: recognising the hidden trajectory and modifying it (Heinz Gisslinger)
  • 15:00–16:15 Session 4 — PV and ET: upstream trajectory change (before it becomes irreversible) — Iron-axis therapeutics in PV: hepcidin mimetics and TMPRSS6-silencing agents — clinical data and positioning (Marina Kremyanskaya)
  • 15:00–16:15 Session 4 — PV and ET: upstream trajectory change (before it becomes irreversible) — Discussion: “Can PV/ET be engineered like CML was?”
  • 16:15–17:15 Session 5 — Vessel-first reality check: thrombosis, cardiovascular burden, and pragmatic prevention — Thrombotic emergencies in MPNs: acute management, atypical sites, and what changes practice (Mariasanta Napolitano)
  • 16:15–17:15 Session 5 — Vessel-first reality check: thrombosis, cardiovascular burden, and pragmatic prevention — Platelets, niche and advanced MF phenotypes: why thrombocytopenia is a biology signal (Giulio Giordano)
  • 16:15–17:15 Session 5 — Vessel-first reality check: thrombosis, cardiovascular burden, and pragmatic prevention — Atrial fibrillation in MPNs: an underrecognised complication reshaping vascular management (Olga Demska)
  • 16:15–17:15 Session 5 — Vessel-first reality check: thrombosis, cardiovascular burden, and pragmatic prevention — Discussion: “What do we treat first when the ‘vessel’ is screaming?”
  • 17:35–18:40 Session 6 — Preclinical Spotlight: why the next trials should work — Invited Talk (Elena Masselli) — Distinguished Chairs (Sara Galimberti, Thomas Fischer); Transcriptomic rewiring of CD34⁺ cells in myelofibrosis: extracellular matrix dysregulation as a driver of marrow fibrosis (15 min)
  • 17:35–18:40 Session 6 — Preclinical Spotlight: why the next trials should work — Tutor + Emerging Talent — Pair 1 (Edoardo Peroni) — Sara Galimberti — Contextualising splenic microenvironment research: from biology to transplant implications (Distinguished Chair / Tutor); Edoardo Peroni — Spatially Resolved Transcriptomics Profiling Reveals Compartmentalised Inflammatory and Fibrogenic Circuits in the Myelofibrosis Spleen (Best Abstract Winner #1, RiseMPN 2025)
  • 17:35–18:40 Session 6 — Preclinical Spotlight: why the next trials should work — Tutor + Emerging Talent — Pair 2 (Enrico La Spina) — Thomas Fischer — Contextualising oxidative stress and signalling in MPN neutrophils: the pathway landscape (Distinguished Chair / Tutor); Enrico La Spina — Uncoupled NRF2 Activation and Persistent Unfolded Protein Response Characterise Neutrophils in Myelofibrosis (Best Abstract Winner #2, RiseMPN 2025)
  • 17:35–18:40 Session 6 — Preclinical Spotlight: why the next trials should work — Discussion: “From bench to trial: what these findings change for combination design.” — Distinguished Chairs: Sara Galimberti, Thomas Fischer
  • 18:40–18:50 Closing Day 1 — Key take-aways and “questions to answer tomorrow.”

DAY 2 — Saturday, 7 November 2026

07/11/2026

  • 08:45–08:50 Welcome Back
  • 08:50–10:00 Session 7 — Patients that force the strategy to be real — Recurrent miscarriage in MPNs: decisions, trade-offs, trajectories (Novella Pugliese)
  • 08:50–10:00 Session 7 — Patients that force the strategy to be real — AYA-MPN: lifelong trajectory engineering starts here (Marta Sobas)
  • 08:50–10:00 Session 7 — Patients that force the strategy to be real — Bleeding syndromes in MPN: the ‘other side’ of vascular medicine (Giorgia Micucci)
  • 08:50–10:00 Session 7 — Patients that force the strategy to be real — Quality of life in polycythaemia vera: iron bioavailability, the phlebotomy burden, and the perception gap between physicians and patients (Giovanni Caocci)
  • 08:50–10:00 Session 7 — Patients that force the strategy to be real — Discussion: “Personalised strategy is not a slogan: what changes Monday morning?”
  • 10:05–10:25 RISE LECTURE II (Giovanni Martinelli) — Distinguished Chair
  • 10:25–10:40 Coffee Break
  • 10:40–11:55 Session 8 — Precision diagnostics to steer combos (and prove modification) — Spatial / imaging-omics of MPN microenvironment: what we can measure now (Jennifer O’Sullivan)
  • 10:40–11:55 Session 8 — Precision diagnostics to steer combos (and prove modification) — CALR and CD47 dynamics: immunologic targets and anti-CALR logic (Ciro Rinaldi)
  • 10:40–11:55 Session 8 — Precision diagnostics to steer combos (and prove modification) — NGS architecture and response-adaptive monitoring: making trials ‘trajectory-aware’ (Paola Guglielmelli)
  • 10:40–11:55 Session 8 — Precision diagnostics to steer combos (and prove modification) — Interpretable scores and composite vascular risk to guide strategy (Andrea Duminuco)
  • 10:40–11:55 Session 8 — Precision diagnostics to steer combos (and prove modification) — Discussion: “If you can’t measure it, you can’t engineer it.”
  • 11:55–12:10 BRIDGE LECTURE II (Fabio Gori) — Standalone — connects diagnostic precision (Session 8) to clinical decision-making (Session 9).
  • 12:10–13:25 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification — Bridge-to-transplant in MF: how modern therapy changes candidacy and timing (Selene Guerzoni)
  • 12:10–13:25 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification — Allo-SCT in older MF: realistic pathways and decision thresholds (Francesco Saraceni)
  • 12:10–13:25 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification — Predicting post-SCT outcomes: how ‘modification’ shows up after the cure attempt (Patrizia Chiusolo)
  • 12:10–13:25 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification — Accelerated and blast phase MPN: recognising the turning point and rewriting the endgame (Jose Torregrosa)
  • 12:10–13:25 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification — Expert Discussant (Tania Jain) — John Mascarenas; Tania Jain (Johns Hopkins) — structured commentary on transplant timing and molecular risk integration
  • 12:10–13:25 Session 9 — When the trajectory accelerates: transplant, blast phase, and the limits of modification — Discussion: “When is ‘enough improvement’ enough to move?”
  • 13:25–14:55 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES — CML: positioning third-generation TKIs and allosteric BCR-ABL1 inhibitors in 2026 practice (Mario Tiribelli)
  • 13:25–14:55 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES — New clinical trials in CML: what they teach us about deep targets and MRD (Srinivas Tantravahi)
  • 13:25–14:55 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES — CML monitoring in 2026: methodologies, treatment-free remission, and the challenge of atypical transcripts (Carmen Fava)
  • 13:25–14:55 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES — Systemic mastocytosis: targeted therapies and real endpoints in advanced disease (Daniela Cilloni)
  • 13:25–14:55 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES — HES: targeted approaches and trajectory control in eosinophil-driven disease (Massimo Breccia)
  • 13:25–14:55 Session 10 — Beyond classical MPN: lessons from CML, mastocytosis, HES — Discussion: “What can MPN steal (ethically) from these playbooks?”
  • 14:55–15:40 Lunch + Poster Walk + Best Poster Award + Industry Symposium 2 — Posters displayed in the networking/lunch area.; Poster Walk co-led by Monica Poggiaspalla and Giovanni Martinelli on behalf of the Scientific Committee.; Industry Symposium 2 runs as a parallel option. Sponsor tbd.; Best Poster Award (~15:15) — Presented by the RiseMPN Scientific Committee. The award includes full hospitality for RiseMPN 2027.
  • 15:40–15:50 Closing Remarks — Key messages, acknowledgements, and preview of RiseMPN 2027.; The RiseMPN Trajectory Statement 2026 will be developed as a post-congress publication.

Dettagli della formazione

Obiettivo formativo
n. 2 · Linee guida - protocolli - procedureObiettivi di sistema
Metodologie didattiche
lezioni magistrali, serie di relazioni su tema preordinato, tavole rotonde con dibattito tra esperti, confronto/dibattito tra pubblico ed esperto/i guidato da un conduttore ("l'esperto risponde")
Verifica della presenza
Firma Di Presenza
Verifica dell'apprendimento
Questionario A Risposta Multipla Online

Responsabili e docenti

RESPONSABILI SCIENTIFICI, MODERATORI
Alessandro LucchesiGerardo Musuraca
MODERATORI
Elisabetta AbbruzzeseClaudio CerchioneNicola GentiliFrancesco MalaspinaGuglielmo MarianiGianantonio Rosti
RELATORI
Giovanni CaocciDaniela CilloniGiulio GiordanoDomenico GirelliSelene GuerzoniPaola GuglielmelliGiovanni MartinelliElena MasselliGiorgia MicucciMaria Santa NapolitanoGiuseppe Alberto PalumboAndrea PatriarcaNovella PuglieseElena RossiFrancesco SaraceniDaniele Tibullo

Razionale scientifico

Dal programma del provider.

Over the past decade, myeloproliferative neoplasms (MPNs) have moved from being viewed as indolent chronic disorders to paradigmatic models of clonal haematopoiesis, vascular injury and systemic inflammation. In RiseMPN 2025 we explored this evolving landscape by focusing on inflamed vessels and clonal survival: how “fire in the blood” and niche remodeling shape thrombosis, fibrosis and disease progression. That meeting asked why disease trajectories diverge. RiseMPN 2026 will ask a bolder question: Can we engineer disease trajectories in MPNs?

The therapeutic toolkit in MPNs is expanding rapidly. JAK inhibition has transformed symptom control and splenomegaly, but has only partially delivered on the promise of disease modification. At the same time, a new generation of agents is emerging: interferons and other immunomodulators; anti-inflammatory and anti-fibrotic approaches; hepcidin and activin-ligand–targeting drugs; epigenetic and transcriptional modulators; p53/MDM2 and BCL2 family inhibitors; rational antithrombotic and cardiometabolic strategies. The central challenge for the next decade is no longer merely what works, but which combinations, in which patients, at which time-point, can genuinely rewrite the natural history of disease.

RiseMPN 2026 is designed as a translational dialogue across three axes: Mechanism → Combination → Trajectory. First, we will map the pathway constellations that matter most for synergy – from JAK/STAT and inflammatory signalling to metabolic stress, niche reprogramming and immune escape. Second, we will critically appraise emerging combination strategies in MF, PV and ET, moving beyond single-agent narratives to consider how layering therapies can achieve fibrosis regression, molecular clearance, vascular protection and durable haematologic remissions. Third, we will confront the strategic questions that increasingly shape daily practice: early versus delayed intensification, add-on versus switch, integration with allogeneic transplant, and the role of real-world data and AI-driven models in guiding these choices.

Central to this discussion is the need to define what we mean by “disease modification” in MPNs. Across the programme we will revisit our endpoints: from spleen volume and symptom scores to dynamic measures of allele burden, bone marrow architecture, clonal competition, cardiovascular risk and quality of life. We will examine how to design disease-modifying trials, how to read intermediate signals along a trajectory, and how to balance efficacy, safety, cost and feasibility in a field where many patients will never see a transplant but all deserve a rational long-term plan.

RiseMPN 2026 therefore aims to be more than an update meeting. It is an invitation to the MPN community to think and act as “trajectory engineers”: to integrate mechanism with clinical reality, combination design with strategic positioning, and innovative endpoints with meaningful benefit for patients. By bringing together basic scientists, translational researchers, trialists, transplant physicians, cardiologists and young investigators around a single guiding question – “Can we engineer disease trajectories in MPNs?” – we hope to co-create the conceptual and practical framework that will define the next era of MPN care.

Obiettivi del corso

Approfondire le più recenti evidenze biologiche, diagnostiche e terapeutiche nelle neoplasie mieloproliferative (mpns), con particolare riferimento ai meccanismi di progressione di malattia, alle strategie di disease modification, alla medicina di precisione, alle terapie di combinazione, al monitoraggio molecolare e al corretto impiego delle nuove opzioni terapeutiche nella pratica clinica.

Domande frequenti

Quanti crediti ECM assegna?
«Risempn 2026 Can We Engineer Disease Trajectories In Mpns?» assegna 14 crediti ECM a fronte di 14 ore di formazione (1 crediti l'ora).
Si svolge online o in presenza?
In presenza: «Risempn 2026 Can We Engineer Disease Trajectories In Mpns?» è un evento residenziale (RES), a Roma (Lazio).
Quando si svolge?
«Risempn 2026 Can We Engineer Disease Trajectories In Mpns?» si svolge dal 6 nov 2026 al 7 nov 2026 a Roma (Lazio).
A quali professioni sanitarie è accreditato?
«Risempn 2026 Can We Engineer Disease Trajectories In Mpns?» è accreditato per Medico Chirurgo, nelle discipline Farmacologia E Tossicologia Clinica, Oncologia, Genetica Medica, Patologia Clinica (Laboratorio Di Analisi Chimico-Cliniche E Microbiologia), Biochimica Clinica e altre 4. Solo chi rientra in queste professioni matura i crediti.
Quanto costa?
«Risempn 2026 Can We Engineer Disease Trajectories In Mpns?» è gratuito: l'iscrizione non ha costi e i crediti valgono esattamente quanto quelli di un corso a pagamento.
Chi eroga il corso?
«Risempn 2026 Can We Engineer Disease Trajectories In Mpns?» è erogato da Xenia Sas Di Mazza Francesca & C., provider ECM accreditato Agenas con id 5090.
Conviene rispetto a un corso FAD gratuito sullo stesso obiettivo?
Dipende da cosa cerchi. Ci sono 4 alternative gratuite sullo stesso obiettivo per medico chirurgo (vedi tabella), alcune online. Questo evento ha senso se ti interessa il tema o se sei vicino a Roma: il costo è zero in entrambi i casi, cambia solo il tempo.
Quanto pesa questo corso sull'obbligo del triennio 2026-2028?
14 crediti sono il 9,3% dei 150 crediti richiesti nel triennio. Con l'esonero o la riduzione per chi ha completato il triennio precedente la quota percentuale sale.
Imposta la tua professione per il calcolo esatto →
C'è un limite ai crediti RES che posso accumulare nel triennio?
No: non esiste un tetto per i crediti da eventi residenziali. Il limite riguarda solo la formazione sponsorizzata (o l'autoformazione), non la tipologia dell'evento.
A cosa serve un credito di area di sistema?
Gli obiettivi di sistema sono meno frequenti nell'offerta ECM rispetto a quelli tecnico-professionali. Nel dossier formativo individuale ogni area vale almeno il 10% del piano: questo corso aiuta a coprire quella quota senza spendere.
Posso sommare più corsi di Xenia Sas Di Mazza Francesca & C.?
Sì, non c'è limite per provider. Xenia Sas Di Mazza Francesca & C. ha 37 corsi in calendario (100% gratuiti, in media 7,1 crediti l'uno).

Alternative sullo stesso obiettivo

  1. Cem Full Immersion Corso Teorico - Pratico
    Datre Srl · RES · entro il 17/10/2026
    16,7 crediti
    €36,53/credito
  2. Percorso Base Destinato Al Personale Delle Autorita' Competenti Di Cui All'articolo 2, Comma 1 Del Decreto Legislativo 27/2021
    Istituto Zooprofilattico Sperimentale Delle Venezie · FAD · entro il 01/11/2026
    50 crediti
    gratis
  3. Master Di I Livello In Management Del Mieloma – Edizione 2026
    Ray Hc S.R.L. · RES · entro il 16/10/2026
    44,2 crediti
    gratis
  4. Eco Expert 2.0 Valutazione Clinica Ed Ecografica Dello Stato Articolare Dei Pazienti Con Emofilia A Con Inibitore E Senza Inibitore
    Mapy Consulenza & Servizi Sas · FSC · entro il 10/12/2026
    30,4 crediti
    gratis
  5. Share The Experience Linee Guida, Pratica Clinica E Applicazioni Dell'ecg
    Summeet Srl · FSC · entro il 20/10/2026
    24,7 crediti
    gratis

ECM in numeri

Come si colloca questo corso

Confronto con il catalogo pubblico Agenas, aggiornato al 30/09/2026. Questo corso è gratuito.

  • Medico Chirurgo: 22.964 edizioni a catalogo, 70,1% gratuite, credito mediano € 22,00
  • Residenziale: 70,8% del catalogo, 67,8% gratuite, credito mediano € 23,81
  • Si svolge in Lazio: 4.308 edizioni con sede nel territorio, 71% gratuite, credito mediano € 24,55.
  • Obiettivo n. 2 (linee guida, protocolli, procedure): lo dichiara il 20,4% del catalogo, con il 68,6% di edizioni gratuite. Il corso è accreditato per 9 discipline; la mediana del catalogo è 7.

Radar delle professioniPrezzi ECMIl conto del triennioI 38 obiettivi formativi

Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Trova ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.

Avvisami sui nuovi corsi e news per la mia professioneSolo quello che riguarda davvero la tua professione, via email. Gratis, e ti disiscrivi quando vuoi.
Iscriviti gratis